Katrien Van Bocxlaer

List of Publications by Year
in descending order

17	512	687363 13	888059 17
papers	citations	h-index	g-index

18	18	18	746
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. Frontiers in Tropical Diseases, 2022, 3, .	1.4	17
2	Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis â€“ challenges and opportunities. RSC Medicinal Chemistry, 2021, 12, 472-482.	3.9	7
3	Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. Pharmaceutics, 2021, 13, 516.	4.5	11
4	Characterization of a new Leishmania major strain for use in a controlled human infection model. Nature Communications, 2021, 12, 215.	12.8	28
5	Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis. Molecules, 2020, 25, 4002.	3.8	35
6	Leishmaniasis immunopathologyâ€"impact on design and use of vaccines, diagnostics and drugs. Seminars in Immunopathology, 2020, 42, 247-264.	6.1	51
7	Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	25
8	A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. PLoS Neglected Tropical Diseases, 2019, 13, e0007373.	3.0	11
9	Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 106-117.	3.4	58
10	Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 129-138.	3.4	44
11	Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
12	Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations FungisomeÂ® and AmBisomeÂ® in murine cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 223-228.	3.4	37
13	Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	28
14	Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
15	Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
16	Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. Journal of Pharmacy and Pharmacology, 2016, 68, 862-872.	2.4	39
17	Drug permeation and barrier damage inLeishmania-infected mouse skin. Journal of Antimicrobial Chemotherapy, 2016, 71, 1578-1585.	3.0	42